Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | LIPE | Q05469 | 8/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673550 | 0.87 | ACACB (0.41) | GPR119LOXL2LIPG | |
| SCHEMBL5267711 | 0.84 | GPR119 (0.62) | GPR119 | |
| SCHEMBL289843 | 0.81 | EGFR (0.41) | GPR119EPHX2 | |
| SCHEMBL6122741 | 0.78 | LOXL2 (0.52) | LOXL2 | |
| SCHEMBL16217413 | 0.77 | GPR119 (0.43) | GPR119 | |
| SCHEMBL21825422 | 0.77 | LIPE (0.44) | GPR119LIPELIPGEPHX2 | |
| SCHEMBL6122282 | 0.76 | LOXL2 (0.52) | LOXL2 | |
| SCHEMBL6121317 | 0.76 | LOXL2 (0.60) | LOXL2 | |
| SCHEMBL5674167 | 0.74 | LIPE (0.62) | LIPELIPGEPHX2 | |
| SCHEMBL5671228 | 0.74 | GPR119 (0.54) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347990-B1 | Peptides having inhibiting activity to nitric oxyde production | ASTELLAS PHARMA INC (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7129243-B2 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1347990-A2 | PEPTIDE MIT INHIBIERENDER AKTIVITÄT ZUR PRODUKTION VON STICKSTOFFMONOXID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002055541-A2 | PEPTIDES HAVING INHIBITING ACTIVITY ON THE PRODUCTION OF NITRIC OXIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | GPR119 118/4885LOXL2 3629/4885LIPE 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.